Meningococcal vaccines

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 975-979

  Collins, Clare L ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Lipopolysaccharide; Meningitis; Neisseria meningitidis; Outer membrane protein; Serogroup; Vaccine

Indexed keywords

EXOTOXIN VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE VESICLE VACCINE; SEROGROUP A MENINGOCOCCUS POLYSACCHARIDE VACCINE; SEROGROUP B MENINGOCOCCUS POLYSACCHARIDE VACCINE; SEROGROUP C MENINGOCOCCUS POLYSACCHARIDE VACCINE; SEROGROUP C PROTEIN POLYSACCHARIDE CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL MENINGITIS; BACTERIAL TRANSMISSION; BACTERIUM CARRIER; BLOOD GROUP TYPING; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; SIDE EFFECT; VACCINATION;

ANIMALS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 0036667133     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Tikhomirov E, Santamaria M, Esteves K: Meningococcal disease: Public health burden and control. World Health Stat Q (1997) 50:170-177.
2. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL: The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis (1999) 180:1894-1901. This review considers the implications for meningococcal vaccine use in light of the changing epidemiology of meningococcal disease recently observed in the US.
3. Pollard AJ, National Committee on Immunization (NACI): Statement on recommended use of meningococcal vaccines. Can Comm Dis Rev (2001) 27:2-36.
4. Communicable Disease surveillance Centre and the Meningococcal Reference Unit: Invasive meningococcal infections, England and Wales, by age and serogroup. http://www.phls.co.uk/facts/Mening/N%20Mening/meni-Quarters.htm 2001.
5. Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, Fleming D: Epidemic serogroup B meningococcal disease in Oregon: The evolving epidemioogy of the ET-5 strain. J Am Med Assoc (1999) 281:1493-1497.
6. Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 129:1307-1326. This classic review describes the importance of humoral antibodies in the human immune response to meningococcal infections.
7. Garcia Rojas A, Bordes Benitez A, Lafarga Capuz B, Vazquez Moreno J, Lopez Villarrubia E, Garcia Castellano P, Solis Romero J: Survey of carriers of Neisseria meningitidis in the health area of Gran Canary. Rev Esp Salud Publica (2000) 74:419-424.
8. Caugant DA, Høiby EA, Magnus P, Scheel O, Hoel T, Bjune G, Wedege E, Eng J, Frøholm LO: Asymptomatic carriage of Neisseria meningitidis in a randomly population. J Clin Microbiol (1994) 32:323-330.
9. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M: Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 137:112-121.
10. Peltola H, Kataja JM, Mäkelä PH: Shift in the age-distribution of meningococcal disease as predictor of an epidemic? Lancet (1982) 2:595-597.
11. Kirsch EA, Barton RP, Kitchen L, Giroir BP: Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience. Pediatr Infect Dis J (1996) 15:967-978. A review of clinical practice and therapeutic strategies in the treatment of meningococcal septicemia.
12. Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ: Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J (1989) 8:8-11.
13. Levin M, Galassini R, De Munter C, Nadel S, Habibi P, Britto J, Booy R: Improved survival in children admitted to intensive care with meningococcal disease. Second Annual Spring Meeting of the Royal College of Paediatrics and Child Health, York, UK (1998):98.
14. Feavers IM: Meningococcal vaccines and vaccine developments. In: Meningococcal Vaccines. Pollard AJ, Maiden MCJ (Eds), Humana Press Inc, Tototwa, NJ, USA (2001):1-22.
15. Gorringe AR, Bracegirdle P, Oliver K, Reddin K, Cartwright K, Feavers I, Fox A, Robinson A: Neisseria lactamica as a vaccine against meningococcal disease. ICAAC (1999) 39:Abs 362.
16. Tang C, Moxon R, Levine MM: For discussion: Live attenuated vaccines for group B meningococcus. Vaccine (1999) 17:114-117.
17. Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä PH: Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis (1980) 142:861-868.
18. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC: Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673-680.
19. Zangwill KM, Stout RW, Carlone GM, Pais L, Harekeh H, Mitchell S, Wolfe WH, Blackwood V, Plikaytis BD, Wenger JD: Duration of antibody response after meningococcal polysaccharide vaccination in US AIR Force personnel. J Infect Dis (1994) 169:847-852.
20. De Wals P, De Serres G, Niyonsenga T: Effectiveness of a mass immunization campaign against serogroup C meningococal disease in Quebec. J Am Med Assoc (2001) 285:177-181.
21. Granoff DM, Gupta RK, Belshe RB, Anderson EL: Induction of immunologic refractorines in adults by meningococcal C polysaccharide vaccination. J Infect Dis (1998) 178:870-874.
22. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER: Safety, immunologenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. J Am Med Assoc (2000) 283:2795-2801.
23. Maslanka SE, Tappero JW, Plikaytis BD, Brumberg RS, Dykes JK, Gheesling LL, Donaldson KB, Schuchat A, Pullman J, Jones M, Bushmaker J, Carlone GM: Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun (1998) 66:2453-2459.
24. Ramsay ME, Andrews N, Kaczmarski EB, Miller E: Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet (2001) 357:195-196. Surveillance data following the introduction of meningococcal serogroup C conjugate vaccine.
25. Morley SL, Pollard AJ: Vaccine prevention of meningococcal disease, coming soon? Vaccine (2001) 20:666-687.
26. Finne J, Leinonen M, Mäkelä PH: Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 2:355-357.
27. Finne J, Bitter-Suermann D, Goridis C, Finne U: An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol (1987) 138:4402-4407.
28. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guamieri V, Seid RC, Shan A, Usinger WR, Tan S et al: Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol (1998) 160:5028-5036.
29. Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J: Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17:2612-2619.
30. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E et al: Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 338:1093-1096.
31. Frasch CE, Zahradnik JM, Wang LY, Mocca LF, Tsai CM: Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotypel 2b protein-group B polysaccharide vaccine. J Infect Dis (1988) 158:710-718.
32. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Høiby EA, Rosenqvist E, Holst J, Nøkleby H, Sotolongo F, Sierra G et al: Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis (1998) 177:683-691.
33. Tappero JW, Lagos R, Ballesteros AM, Pikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nokleby H et al: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. J Am Med Assoc (1999) 281:1520-1527.
34. Sierra GV, Campa HC, Varcacel NM, García IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodríguez CR, Terry MH: Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 14:195-204; discussion 208-110.
35. Zollinger WD, Mandrell RE, Griffiss JM, Altieri P, Berman S: Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest (1979) 63:836-848.
36. Pollard AJ, Frasch C: Development of natural immunity to Neisseria meningitidis. Vaccine (2001) 19:1327-1346.
37. Baker M, McNicholas A, Garrett N, Jones N, Stewart J, Koberstein V, Lennon D: Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J (2000) 19:983-990.
38. Griffiss JM, Brandt BL, Broud DD, Goroff DK, Baker CJ: Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis (1984) 150:71-79.
39. Zollinger WD, Moran EE, Devi SJ, Frasch CE: Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun (1997) 65:1053-1060.
40. Plested JS, Makepeace K, Jennings MP, Gidney MA, Lacelle S, Brisson J, Cox AD, Martin A, Bird AG, Tang CM, Mackinnon FM et al: Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun (1999) 67:5417-5426.
41. Plested JS, Ferry BL, Coull PA, Makepeace K, Lehmann AK, MacKinnon FG, Griffiths HG, Herbert MA, Richards JC, Moxon ER: Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry. Infect Immun (2001) 69:3203-3213.
42. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL et al: Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287:1816-1820. This paper describes the use of the entire genome of a virulent strain of Neisseria meningitidis to identify potential vaccine candidates, which were tested to see if they could induce a bactericidal antibody response in mice.
43. Rappuoli R: Reverse vaccinology, a genome-based approach to vaccine development. Vaccine (2001) 19:2688-2691.
44. Sun YH, Bakshi S, Chalmers R, Tang CM: Functional genomics of Neisseria meningitidis pathogenesis. Nat Med (2000) 6:1269-1273.